Advanced search
Start date
Betweenand
Related content

ACYL-HYDRAZONE AND OXADIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF

OfficeCNIPA
Document type:Patent
Inventor(s): Ricardo José Nunes; Alessandra Mascarello; Rosendo Augusto Yunes; Taisa Regina Stumpf; Paulo Cesar Leal; José Andres Yunes; Carolina Pereira De Souza Melo; Rafael Renatino Canevarolo; Louise Domeneghini Chiaradia; André Bortolini Silveira; Anqelo Brunelli Albertoni Laranjeira
Abstract

The present invention relates to acyl-hydrazone compounds, in particular 3,4,5-trimethoxyphenyl-hydrazide derivatives, oxadiazole analogs and other similar compounds thereof, and to their use in the treatment of diseases associated with cell proliferation Drug use in various diseases such as leukemia, including acute lymphoblastic leukemia (ALL), tumors and inflammation. An acyl-hydrazone having similar activity to the compound used as a standard in the experiment (colchicine) has been obtained. The greater selectivity of the compounds according to the invention is an important feature associated with less side effects compared to drugs currently used in clinical therapy. Synthetic acyl-hydrazones, more particularly compounds 02 and 07, exhibited significant anti-leukemic activity, suggesting that 02 and 07 may be useful in the treatment of leukemia, especially acute lymphoblastic leukemia (ALL), tumors and diseases such as inflammatory Drug prototypes or drug candidates for other proliferative diseases. In addition to selectivity studies in healthy human lymphocytes, the mechanism of action of the most active compounds was determined by testing using DNA microarrays followed by chip indication.


FAPESP's process: 09/04167-1 - Metabolomics of methotrexate resistance in acute lymphoblastic leukemia
Grantee:Rafael Renatino Canevarolo
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support Opportunities: Scholarships in Brazil - Master

FAPESP's process: 12/11952-0 - Methotrexate resistance is directly associated with glutathione concentration in acute lymphoblastic leukemia cell lines
Grantee:Rafael Renatino Canevarolo
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support Opportunities: Scholarships in Brazil - Doctorate

FAPESP's process: 08/02106-2 - IGFBP7 role in chemotherapy resistance of Pediatric Acute Lymphoblastic Leukemia
Grantee:Angelo Brunelli Albertoni Laranjeira
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support Opportunities: Scholarships in Brazil - Doctorate

FAPESP's process: 12/03039-2 - IGFBP7 and insulin/IGFs in Childhood Acute Lymphoblastic Leukemia chemoresistance
Grantee:Angelo Brunelli Albertoni Laranjeira
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support Opportunities: Scholarships in Brazil - Post-Doctoral

FAPESP's process: 14/08247-8 - Preclinical studies of novel inhibitors of DNA methyltransferase in acute leukemia
Grantee:Nathalia Moreno Cury
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support Opportunities: Scholarships in Brazil - Doctorate